Logistic regression analysis of PTPN22 C1858T on the positivity for GAD and IA2 autoantibodies in type 1 diabetic patients
| Model tested . | χ2 . | Degrees of freedom . | P value . |
|---|---|---|---|
| GAD positivity (n = 491) | |||
| Disease duration at sampling | 28.742 | 1 | 8 × 10−8 |
| Age at onset | 16.196 | 1 | 6 × 10−5 |
| HLA-DR genotype | 20.537 | 5 | 0.001 |
| PTPN22 genotypes (C/C, C/T, T/T) | 9.694 | 2 | 0.008 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 6.668 | 1 | 0.01 |
| GAD+ (disease duration ≥10 years, n = 338) | |||
| Disease duration at sampling | 5.660 | 1 | 0.02 |
| Age at onset | 12.380 | 1 | 0.0004 |
| HLA-DR genotype | 11.603 | 5 | 0.041 |
| PTPN22 genotypes (C/C, C/T, T/T) | 13.950 | 2 | 0.0009 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 6.402 | 1 | 0.01 |
| GAD positivity (disease duration <10 years, n = 153) | |||
| Disease duration at sampling | 3.542 | 1 | 0.06 |
| Age at onset | 3.953 | 1 | 0.5 |
| HLA-DR genotype | 9.266 | 5 | 0.1 |
| PTPN22 genotypes (C/C, C/T, T/T) | 0.796 | 2 | 0.67 |
| IA2+ (n = 492) | |||
| Disease duration at sampling | 35.846 | 1 | 2 × 10−9 |
| Age at onset | 12.085 | 1 | 0.0005 |
| HLA-DR genotype | 55.481 | 5 | 1 × 10−10 |
| PTPN22 genotypes (C/C, C/T, T/T) | 7.877 | 2 | 0.02 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 2.992 | 1 | 0.08 |
| Model tested . | χ2 . | Degrees of freedom . | P value . |
|---|---|---|---|
| GAD positivity (n = 491) | |||
| Disease duration at sampling | 28.742 | 1 | 8 × 10−8 |
| Age at onset | 16.196 | 1 | 6 × 10−5 |
| HLA-DR genotype | 20.537 | 5 | 0.001 |
| PTPN22 genotypes (C/C, C/T, T/T) | 9.694 | 2 | 0.008 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 6.668 | 1 | 0.01 |
| GAD+ (disease duration ≥10 years, n = 338) | |||
| Disease duration at sampling | 5.660 | 1 | 0.02 |
| Age at onset | 12.380 | 1 | 0.0004 |
| HLA-DR genotype | 11.603 | 5 | 0.041 |
| PTPN22 genotypes (C/C, C/T, T/T) | 13.950 | 2 | 0.0009 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 6.402 | 1 | 0.01 |
| GAD positivity (disease duration <10 years, n = 153) | |||
| Disease duration at sampling | 3.542 | 1 | 0.06 |
| Age at onset | 3.953 | 1 | 0.5 |
| HLA-DR genotype | 9.266 | 5 | 0.1 |
| PTPN22 genotypes (C/C, C/T, T/T) | 0.796 | 2 | 0.67 |
| IA2+ (n = 492) | |||
| Disease duration at sampling | 35.846 | 1 | 2 × 10−9 |
| Age at onset | 12.085 | 1 | 0.0005 |
| HLA-DR genotype | 55.481 | 5 | 1 × 10−10 |
| PTPN22 genotypes (C/C, C/T, T/T) | 7.877 | 2 | 0.02 |
| Submodel: dominant vs. additive models | |||
| PTPN22 T carrier/noncarrier vs. PTPN22 genotypes | 2.992 | 1 | 0.08 |
The full model takes into account the duration of disease, age at onset, HLA-DR genotypes (six genotypes with three alleles, DR3, DR4, and non-DR3 non-DR4), and PTPN22 genotype.